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Abstract
Clostridium difficile is a bacterium widely distributed in the human environment. In the last decade the incidence and se-
verity of Clostridium difficile infection has grown, particularly in Europe and North America, making it one of the more common 
nosocomial infections. A group particularly susceptible to Clostridium difficile infection are patients with inflammatory bowel 
disease, especially those with involvement of the colon. This paper presents relevant data on Clostridium difficile infections in 
inflammatory bowel disease patients, including epidemiology, pathogenesis, diagnosis and treatment.
Introduction
Clostridium difficile is a gram positive, spore-produc-
ing anaerobic rod. It was first isolated by Hall and O’Toole 
in 1935 [1]. In 1974, Tedesco et al. reported diarrhoea 
in 21% of patients treated with clindamycin, with half 
of them displaying pseudomembranes on endoscopy 
[2]. The set of symptoms caused by Clostridium difficile 
infection is referred to as either Clostridium difficile- 
associated disease (CDAD) or Clostridium difficile Infec-
tion (CDI), and these terms are often used interchange-
ably. In the last decade there was an increase in both 
the frequency and severity of CDI. It is more common in 
hospitalised patients; hence patients hospitalised with 
inflammatory bowel disease (IBD) are a particularly vul-
nerable group. The CDI infection in these patients occurs 
more frequently and often runs a more severe course 
than observed in the general population [3, 4].
Epidemiology
The incidence of CDI in patients with IBD depends 
the amount of the GI tract consumed by, as well as the 
extent of, the disease. Ricciardi et al. published the 
largest existing cohort study, which followed more than 
350,000 patients with IBD over 10 years in the Unit-
ed States. The study showed CDI in 2.8% of patients 
with ulcerative colitis (UC), and in 1% of patients with 
Crohn’s disease (CD) [5]. Nguyen et al. evaluated CDAD 
incidence in patients hospitalised between 1998 and 
2004 and noted that the incidence of CDI in patients 
with UC was 3.73%, in patients with CD it was 1.09% 
while only 0.45% of patients in the general population 
became infected with CDI. Additionally, a two-fold in-
crease in the incidence of CDAD in patients with UC, 
from 2.66% to 5.12%, was noted during seven years 
of observation [6]. Issa et al. found that the incidence 
of CDAD in patients with IBD increased from 1.8% in 
2004 to 4.6% in 2005, and patients with IBD involv-
ing the colon tended to be infected more frequently [7, 
8]. Ananthakrishnan et al. found patients with IBD and 
CDAD were hospitalised more frequently, and that the 
frequency grew over time from 24/1000 cases in 1998 
to 39/1000 cases in 2004 for UC patients and 8/1000 in 
1998 to 12/1000 in 2004 for CD patients [9].
Thus, the last decade has seen an increase in the 
frequency and severity of CDAD in patients with IBD. 
The CDI is more common among patients with UC and 
CD when compared to the general population. The risk 
of disease is higher in adults with UC than among those 
with CD. Such differences were not observed in children 
[10, 11].
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Risk factors
The IBD is an independent risk factor for CDI, with 
an approximately 3-fold increased risk compared with 
non-IBD patients. Proven risk factors for CDAD in pa-
tients with IBD include older age, as well as antibiotic 
or steroid use. The most significant factor in the de-
velopment of CDAD in patients with IBD is antibiotic 
therapy. Approximately 60% of patients with IBD report 
the use of antibiotics prior to the development of CDAD. 
Many antibiotics can lead to the development of CDAD; 
however, clindamycin, third-generation cephalosporins, 
fluoroquinolones and broad-spectrum penicillins seem 
to be most frequently implicated [12]. Another risk fac-
tor is treatment with glucocorticoids. In a large cohort 
study in 2009, Schneeweiss et al. showed a three-fold 
higher risk of CDAD in patients with IBD treated with 
steroids, with no correlation between dose and duration 
of use [13]. Studies on other immunosuppressants and 
immunomodulators, including azathioprine, 6-mercap-
topurine, methotrexate and infliximab, are ambiguous 
or have only been carried out in small groups [4]. Old 
age is also a risk factor in patients with IBD, though 
the average age of developing CDAD is lower for IBD 
patients than in the general population. One study of 
51 patients with IBD showed that patients with more 
extensive involvement of the colon had a higher risk 
of developing CDAD. Additional research is needed to 
investigate this issue [14]. Data is lacking concerning 
the prevalence of Clostridium difficile BI/NAP1/027, 
a particularly virulent form of Clostridium difficile char-
acterised by a severe course, in patients with IBD. One 
study assessed the frequency of specific strains of CD in 
patients with clinical remission of UC or CD and demon-
strated that of the seven toxin-producing ribotypes, 
only R015 was common to both diseases [15].
Pathogenesis
Virulence factors produced by Clostridium difficile 
include enzymes such as collagenase, hyaluronidase, 
chondroitin-sulphatase and, most importantly, toxins. 
The most important in the pathogenesis of CDI are tox-
ins A and B, which are both enterotoxic and cytotoxic, 
although traditionally toxin A is defined as the entero-
toxin and toxin B is identified as the cytotoxin. The pro-
duction of these toxins is regulated by the following 
genes: tcdA, tcdB, tcdC, tcdD and tcdE [3]. Some strains 
of Clostridium difficile produce a third toxin called bi-
nary toxin, whose role is still uncertain. Toxins A and 
B cause structural changes of the cytoskeleton of en-
terocytes, which results in their shedding and a local 
inflammatory reaction in response. In the most severe 
cases, CDAD will cause micro ulcerations covered with 
mucous from shed epithelial cells [12, 16, 17]. In the 
pathogenesis of CDAD many cytokines also have an im-
portant role, mainly IL-8, but IL-1β, IL-6, TNF, IFN-γ and 
leukotriene B4 are often present [18, 19]. It is not clear 
what pathogenic factors contribute to CDI in patients 
with IBD. Presumably it is the result of a weakening of 
the immune response in the setting of a chronic inflam-
matory disease, localised compromise of the barrier 
function of the GI tract, immunosuppression as a result 
of treatment of the primary disease and disorders of 
the intestinal flora.
The clinical picture
For more than 30 years ago, La Mont and Thraka 
pointed to the importance of CDI in exacerbations of 
IBD [20]. Just as in the general population, the clinical 
picture of CDI in patients with IBD may vary from as-
ymptomatic carriers, with various severity of diarrhoea 
to the most severe, life-threatening forms of colitis. It is 
often difficult to distinguish between CDI and an IBD 
exacerbation. Moreover, patients with IBD tend to have 
an unusual presentation of CDAD: for example diar-
rhea with blood in a young person, not hospitalized 
before. These patients undergo more frequent endos-
copy and surgical procedures, and are hospitalised more 
frequently with longer hospital stays, both of which are 
risk factors for CDI. The CDAD in patients with IBD is 
characterised by more severe disease course and higher 
mortality compared with the general population [12]. 
The inflammatory process usually involves the colon, 
but may include the small intestine, particularly in pa-
tients post colectomy, as well as those who have inflam-
mation of the reservoir (pouchitis) [3, 4].
Recognition
The CDI diagnosis is based on the detection of Clos-
tridium difficile toxins directly in the stool, most often 
by ELISA. This is a low-cost test characterised by short 
execution time (about 1–2 h), sensitivity of 75–85% and 
a specificity of 95–100% in the general population. In 
patients with IBD, ELISA has a lower efficacy, reaching 
54% in the Ananthakrishnan et al. study [9]. The gold 
standard for diagnosis is a bacterial cytotoxicity assay 
(CYTA cytotoxin assay test) under culture conditions; 
however, it is rarely performed because of its complex-
ity and a much longer test time (48–72 h). Other tests 
available include: breeding Clostridium difficile aimed 
mainly for epidemiological reasons, tests to detect Clos-
tridium difficile antigens, and PCR. Another EIA test is 
based on the detection of glutamine dehydrogenase 
(GDH), a metabolic enzyme that is produced almost ex-
clusively by Clostridium difficile. The test has good sen-
sitivity but poor specificity because it detects colonisa-
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tion of Clostridium difficile. To improve CDAD diagnosis 
the GDH test can be combined with an ELISA-toxin test. 
If the test for GDH is negative the specimen is negative, 
if both tests are positive the specimen is positive, if the 
GDH test is positive and ELISA-toxin test negative an al-
ternative test, such as cytotoxin or PCR test, is required 
[21, 22].
In patients with IBD, diagnostic tests should be 
carried out with suspicion of CDAD each time there is 
worsening of the underlying disease [12, 23]. Screen-
ing for CDI in patients without symptoms is not recom-
mended in the general population, which is currently 
the same recommendation as for patients with CDI. 
Although it still requires further evaluation, there is 
more evidence that even patients with ulcerative colitis 
in remission experienced episodes of diarrhoea with 
blood [4].
Endoscopy has low diagnostic sensitivity in the di-
agnosis of CDAD; much lower in IBD than in the general 
population [3]. Ben-Horin et al. showed pseudomem-
branes in 50% of patients with CDI in the general popu-
lation, while only 13% of patients with IBD had pseudo-
membranes. This test remains an important diagnostic 
tool in the event of complications, unless contraindica-
tions are present [24].
Treatment
The optimal treatment of patients with CDI and 
IBD, and especially in the exacerbation of symptoms of 
IBD, has not been clearly defined. It is not established 
whether the medical treatment of IBD should be con-
tinued or modified, especially when concerning immu-
nomodulatory drugs [3]. Treatment similar to that of 
the general population is indicated in these cases, but 
its effectiveness is different in patients with IBD. Treat-
ment of mild to moderate CDAD in the general popu-
lation consists of 500 mg of metronidazole orally every 
8 h for 10–14 days, or 125–500 mg of vancomycin every 
6 h for 10–14 days [3]. In severe infection, the drug of 
choice is vancomycin at doses of up to 2 g per day. In 
the event of complications, oral vancomycin is recom-
mended (dosing as above) in combination with 500 mg 
intravenous metronidazole every 8 h. In addition, it is 
recommended to discontinue the antibiotic that con-
tributed to the onset of CDAD and replace it with an-
other if necessary. The cessation of antibiotics causes 
withdrawal symptoms in up to 25% of patients in the 
general population, but patients with IBD have not been 
separately studied. The efficacy of treatment with met-
ronidazole or vancomycin in the general population is 
high at 95% and 99%, respectively [23, 25–27]. The pro-
portion of unsuccessful therapy with metronidazole in 
IBD is higher than in the general population, and only 
up to 50% of these patients will be effectively treated 
with this drug [7, 28]. Given the more severe CDAD in 
patients with IBD and the higher risk of complications, 
many authors recommend the use of vancomycin as 
first-line drug therapy in patients with a high proba-
bility of CDAD in the course of IBD, even before test 
results are received [3, 10, 12]. Drugs such as rifaximin, 
bacitracin, nitazoxanide, vancomycin and metronidazole 
did not have higher efficacy; only teicoplanin had an 
insignificant increase in efficacy [3, 29]. Data on immu-
nomodulatory treatment are equivocal. Ben-Horin et al. 
conducted a retrospective, multicentre study, looking 
at 155 patients with IBD hospitalised for CDAD treat-
ed with an antibiotic and an immunomodulator (glu-
cocorticoids, thiopurine, methotrexate, cyclosporine, 
tacrolimus or biological agents) or just an antibiotic. In 
12% of patients with IBD treated with immunomodula-
tory drugs, death or colectomy was reported while no 
such outcomes were observed in the group of patients 
treated only with antibiotics. Of the assessed immuno-
modulatory drugs, only cyclosporine showed no nega-
tive effects [30]. More recent studies on infliximab also 
showed no such outcomes [13]. It should be noted, 
however, that part of the compared studies related to 
an earlier period, when the role of CDI in patients with 
IBD was not fully understood, and therefore probably 
the median time to diagnosis and initiation of therapy 
was longer and the course of the disease more severe 
[12]. There is little data on the recurrence of CDAD in 
patients with IBD. Noteworthy studies have been car-
ried out by Rodemann et al., who showed a lower re-
lapse rate among patients with IBD than in the gener-
al population (0.1% vs. 8.7%) [31]. Further studies are 
needed to assess the recurrence of CDI, but it should be 
noted that when they occur, treatment regimens should 
be the same as those recommended as in the general 
population [25, 26].
There are promising  data on the efficacy of the 
treatment of patients with IBD using the new antibiotic 
– fidaxomicin. It is a macrolide antibiotic with a narrow 
spectrum of bactericidal activity mainly against certain 
Gram-positive pathogens, characterised by high efficacy 
against Clostridium difficile and no effect on the phys-
iological bacterial flora of the intestine. The safety of 
fidaxomicin was proven in two large phase III clinical tri-
als in which more than 1100 patients took part. Study 
of fidaxomicin, 200 mg orally twice daily, compared 
with oral vancomycin, demonstrated similiar clini-
cal response and superior sustained responses with 
a decrease in recurrences (13% vs. 24% with vanco-
mycin treatment) [3, 32].
The role of probiotics in the treatment and preven-
tion of CDAD in the general population is not fully un-
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derstood. Some studies suggest a positive effect of Sac-
charomyces boulardii in particular, but these tests lack 
proper standardisation as they included small patient 
populations. There are no data on the role of probiotics 
in the treatment of CDAD in patients with IBD. Perhaps 
research on monoclonal antibodies will help improve 
the possibility of preventing CDI recurrence [26, 33, 34].
Summary
In the last decade the bacterium Clostridium difficile 
has become one of the most important nosocomial infec-
tions. Patients with IBD comprise a special subset of this 
population. They are characterised by not only a higher 
risk of developing CDAD due to regular use of immuno-
modulatory medications and frequent hospitalisations, 
but they also tend to have a more severe disease course, 
more frequent complications and higher mortality. In 
each patient with acute IBD, concomitant CDI should be 
confirmed or excluded by ELISA. The CDI in patients with 
IBD should be treated with oral vancomycin 125 mg every 
6 h for 14 days. Although we are starting to get a better 
understanding of CDI in the course of IBD, there are still 
many issues that require further study.
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